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CASE STUDY
Hospitalization cost of conventional 
psychiatric care compared to broad-spectrum 
micronutrient treatment: literature review 
and case study of adult psychosis
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Abstract 
Background: Healthcare costs are skyrocketing, with mental health treatment amongst the most expensive, espe-
cially when hospitalization is involved. According to the Mental Health Commission of Canada, one in five Canadi-
ans is living with a mental disorder in any given year, at an annual cost of $50 billion. In light of this societal burden, 
alternative approaches are being evaluated, such as brief psychotherapy by phone, peer support, and, as part of the 
emerging field of nutritional mental health, treatment with micronutrients (minerals and vitamins). Effectiveness of 
micronutrients has been demonstrated for many types of psychiatric symptoms, in about 45 studies of formulas that 
are either multinutrient (e.g., several B vitamins) or broad-spectrum (usually over 20 minerals and vitamins). Although 
this literature demonstrates therapeutic benefits, the potential economic impact of micronutrient treatment has been 
evaluated in only one case study of childhood psychosis.
Methods: The current case study was initiated to evaluate mental health-related hospitalization costs from 1997 to 
2003 for a female adult diagnosed with various mood and psychotic symptoms. She was treated for the first 5 years 
with conventional methods and then subsequently with a broad-spectrum micronutrient formula.
Results: The patient’s annual mental health hospitalization costs during conventional treatment averaged $59,864 
across 5 years (1997–2001), with a peak annual cost of about $140,000. Since transitioning to broad-spectrum micro-
nutrients, she has incurred no provincial hospitalization costs for mental health care, though her self-funded costs are 
currently $720/year for the micronutrients.
Conclusion: Further exploration of the treatment of mental health problems with broad-spectrum micronutrient 
formulas has the potential to make two significant contributions: improved mental health, and decreased costs for 
governments.
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Introduction
Most societies are concerned about the ever-increas-
ing costs of healthcare, especially for mental disorders. 
In Canada, where it is estimated that one in five people 
experience mental illness in any given year, the annual 
direct cost of mental health treatment currently exceeds 
$50 billion and is expected to rise to over $100 billion in 
the 2020s [1]. Alternative approaches are being evalu-
ated with increasing frequency, including various types 
of psychosocial and peer support which may prevent 
subsequent expensive hospitalization or long-term phar-
maceutical costs [2]. Another type of mental health treat-
ment whose effectiveness is increasingly reported in the 
medical literature involves the use of minerals and vita-
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This paper briefly reviews the research on micronu-
trient treatment of mental health disorders, including 
the biologic rationale for this approach, and then sum-
marizes a previously published pediatric case study of 
psychosis which provided a comparison of the health 
cost of conventional psychiatric care versus micronutri-
ent treatment. Subsequently, a new case study of psy-
chosis is presented, evaluating hospitalization costs of 
an adult treated first with conventional psychiatric care 
for five years (1997–2001), and then with micronutrients 
(2002–present).
Background
Micronutrient treatment of mental health disorders
In the past 15 years, there have been over 25 reports of 
mental health benefits from very broad-spectrum for-
mulas consisting of more than 20 minerals and vitamins 
[3]. If one adds these results to the number of studies of 
multinutrient formulas consisting of just a few minerals 
or vitamins (e.g., the evaluation of B complex formulas), 
there are approximately 45 empirical reports, at least 25 
of which were randomized controlled trials (RCTs), and 
all of which are recent [3]. The following is a review of 
the use of broad-spectrum mineral–vitamin combina-
tions for treating several individual mental symptoms 
and disorders.
Aggressive behaviors and conduct violations have 
been studied in preadolescent and adolescent students 
in working-class public schools (two RCTs) and in incar-
cerated adolescents and young adults (three RCTs). All 
five RCTs of broad-spectrum micronutrient treatments 
(involving 23–25 micronutrients) have shown marked 
effects on major disciplinary violations and on aggres-
sive behavior, with 26–47% reductions in the frequency 
of conduct violations [4–8]. In three of these studies, the 
formulations included omega fatty acids, but two did not 
and the results were similar. Although these five positive 
RCTs (with no negative RCTs) are probably sufficient to 
justify implementation in correctional settings, changing 
policies in such institutions can take many years.
Attention deficit hyperactivity disorder (ADHD) 
appeared to be effectively treated with broad-spectrum 
micronutrients in one RCT in adults and nine open-
label studies in youth and adults. The RCT with adults 
included 80 individuals [9]: micronutrients produced 
greater changes than placebo in both hyperactivity/
impulsivity (intent to treat effect sizes (ES) of 0.46–0.67) 
and inattention (ES 0.33–0.62) on both patient and family 
ratings; clinician ratings on individual items were mixed 
but revealed greater improvement in overall psychiatric 
functioning on micronutrients than placebo (ES 0.53–
0.57). Two open-label within-subject crossover stud-
ies (using ABAB designs) of 8–15 year olds with ADHD 
showed significant on–off symptom control on measures 
of ADHD, conduct, and mood [10, 11].
Mood disorders have shown improvement in 16 open-
label reports in adults and youth with bipolar disorder 
and major depressive disorder (MDD) [reviewed in 9, 
12]. After 4–8 weeks of treatment with broad-spectrum 
micronutrient formulas, approximately 50–80% of clients 
with bipolar disorder displayed better scores on measures 
of mania and/or depression. In addition, most patients 
taking conventional drugs were able to completely dis-
continue them (with follow-up for at least 6 months). No 
RCT has yet been reported that selected participants spe-
cifically for MDD, but post hoc analysis of one trial with 
adults with ADHD [9] examined a subsample of partici-
pants who met criteria at baseline for major depression. 
Among the 21 adults with moderate or severe depres-
sion at baseline (Montgomery–Asberg depression rating 
scale score  ≥20), the observed antidepressant effect of 
broad-spectrum micronutrients was substantial (ES 0.64, 
p  <  0.04). Although still preliminary, it is important to 
note that these post hoc findings suggest antidepressant 
benefits comparable to the effects of conventional antide-
pressants. An open-label study of 10 preadolescents with 
bipolar disorder showed a 45% decrease in mania scores 
and a 37% decrease in depression scores on intent-to-
treat analysis [13]. These findings are clearly promising, 
and dedicated RCTs on subjects recruited for mood dis-
orders are needed.
Mood in nonclinical samples has been examined in 
many studies, with no consistent effects at recommended 
daily allowance (RDA) dosing levels. However, a meta-
analysis found that formulations with higher doses of B 
vitamins had more effect on mood ratings—especially 
when the vitamin B doses were 5–10 times above RDA 
levels [14].
Anxiety and resilience to stress. At least 10 RCTs 
have demonstrated that broad-spectrum micronutri-
ents reduced stress and anxiety in nonclinical sample; 
i.e., “normal” people in a variety of situations, such as 
the aftermath of natural disasters. Two RCTs conducted 
after earthquakes [15] and floods [16] showed reduced 
acute stress and anxiety scores; in one [15], the preva-
lence of probable post-traumatic stress disorder (PTSD) 
decreased from 65 to 19% after one month of treatment, 
while the control group remained unchanged. These two 
RCTs suggest that broad-spectrum micronutrients could 
be an inexpensive public health intervention for normal 
populations following natural disasters.
In summary, there is evidence for the beneficial effects 
of broad-spectrum micronutrients on diverse mental 
health targets, although much more research is needed. 
The strongest evidence includes RCTs on violent and 
nonviolent conduct problems, as well as on ADHD. In 
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addition, there are strongly suggestive data on mood dis-
orders, as well as some additional reports on anxiety dis-
orders, obsessive–compulsive disorder, autism spectrum 
disorder, and substance abuse disorders [3].
In contrast, single micronutrients show limited 
promise, and only as augmentation agents (not as 
monotherapies) [17]. In other words, broad-spectrum 
micronutrients appear to have greater potential to mod-
ify central nervous system function in more pervasive 
and potent ways.
Biologic rationale of micronutrient treatment
Micronutrients are essential throughout the central 
nervous system to ensure optimal function [18]. One 
way in which they fulfill this role is to serve as cofac-
tors for the enzymatic activity required in every meta-
bolic step involving synthesis of neurotransmitters. They 
also feed our mitochondria, present in every cell in our 
brain and body, thereby providing an essential function 
in combatting excessive oxidative stress and inflamma-
tion [18]. Micronutrients are also required for regulatory 
proteins such as transcription factors that regulate gene 
expression and epigenetic effects. As just one example 
of how pervasive their functions are, the dietary min-
eral zinc has defined roles in over 100 types of enzymes 
that are required in the mammalian brain for optimal 
metabolism.
There have been numerous reports demonstrating 
micronutrient deficiencies in the modern diet, in part 
due to the over-reliance on highly processed foods. And 
there is a strong consensus from nutritional epidemiol-
ogy studies that people with higher intakes of highly 
processed food have more symptoms of depression and 
anxiety; in some longitudinal analyses, the dietary pat-
tern of highly processed food intake has been shown to 
precede onset of the psychiatric disorders, indicating that 
the way we eat may be a risk factor for mental health dis-
orders [19].
Pediatric case study comparing costs of conventional vs 
micronutrient treatment
Although two published case studies of psychosis have 
demonstrated successful remission of symptoms with 
broad-spectrum micronutrient formulas [20, 21], only 
one of those determined the potential economic impact 
of treating mental health problems in this manner [21]. 
That case was a child aged 10 diagnosed with increasingly 
severe anxiety, then obsessive–compulsive disorder 
(OCD), psychosis with visual and auditory hallucina-
tions, and delusions. As an inpatient for six months in a 
specialized pediatric mental health unit at a tertiary care 
hospital, he was trialed on many psychiatric medications, 
resulting in no improvement: at entry, his Children’s 
Global Assessment Scale score was 35 out of 100 (indica-
tive of very low functioning), and at discharge, it was still 
35 out of 100. At the end of 6 months, the child was sent 
home and referred to outpatient psychiatric care, where 
his parents requested that he be treated with one of the 
broad-spectrum micronutrient formulas1 that had been 
studied. Daily ratings were collected during the following 
year from the boy’s parents (who evaluated symptoms of 
OCD and psychosis) and from the child himself (who 
evaluated his own auditory and visual hallucinations). A 
cross-tapering protocol was followed (increasing nutri-
ents while decreasing medications), and by one month, 
the child was medication-free. By 6 months, most of his 
symptoms were gone and he was leading a fairly normal 
life. A year later, he was discharged from the outpatient 
clinic with a significantly improved score of 70 on the 
Children’s Global Assessment Scale; all diagnoses had 
remitted. This child has been followed now for seven 
years, and he remains symptom-free and he is compliant 
with taking his nutrient capsules. In May 2015, he gradu-
ated from high school and he now holds a part-time job.
A health economist retrieved the provincial healthcare 
costs for the child’s six months of inpatient care, as well 
as for the six months of outpatient care immediately fol-
lowing his discharge while he was taking micronutrients. 
The cost of micronutrients and some outpatient visits in 
the second 6 months was <2% of the prior 6 months of 
inpatient treatment. The important difference, of course, 
was the remission of psychiatric symptoms while taking 
micronutrients (a result not seen in the medication tri-
als). However, a second notable difference was that the 
much larger cost of inpatient care was incurred by the 
provincial health care system, while his ongoing, suc-
cessful treatment with micronutrients is managed by the 
family at a cost of about $150/month.
This child’s positive response while taking micronutri-
ents was consistent with the published clinical trials [3, 
12], and the cost analysis added to our understanding of 
the potential societal benefit of exploring this treatment 
option. We present here a new case report that compares 
the costs incurred by an adult treated initially with con-
ventional medications and later with micronutrients.
Current case report
History
“Marie” was first treated for a psychiatric illness at the 
age of 33 in February 1997 in the province of Ontario. 
1 The formula used in all three case studies is EMPowerplus, marketed by 
Truehope Nutritional Support. Variations of this formula, all of which have 
been developed by two companies in Alberta, Canada, have been sold as 
EMPower, EMPowerPlus, EMPowerPlus Advanced, Truehope EMP, Q96, 
and Daily Essential Nutrients.
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She had been adopted at 3 months of age and was later 
told that substance use issues, mental health challenges, 
and suicide were reported in her biological relatives. 
Marie describes her childhood as having been associ-
ated with hyperactivity, but as an adult, she was a very 
high functioning and hardworking business executive. 
She left her job in December 1996 as her mental health 
deteriorated. The psychiatric reports indicate she had not 
previously missed work for any psychiatric reasons. By 
February 1997, she was having periods of psychosis for 
which she was hospitalized.
Marie’s diagnoses from 1997 to December 2001 (when 
she began micronutrients) included bipolar disorder 
(with psychotic symptoms), schizoaffective disorder, 
depression, and post-traumatic stress disorder. This vari-
ety of diagnoses is not unusual for a serious psychiatric 
problem that is treated in several locations over a period 
of several years. The psychiatric reports indicate she 
spent most of those years in and out of hospital; Marie 
herself estimates she was an inpatient about 70% of the 
time.
Methods
Marie contacted one of the study authors (BJK) to request 
that this cost analysis be carried out, as she has spoken 
publicly about her struggles with mental challenges, and 
her perception of wellness attained by using micronutri-
ent treatment. She provided her health care numbers for 
each of the provinces in which she resided from 1997 to 
the present, and she signed a consent form approving 
the work and its publication. Consultation was sought 
regarding the appropriateness of a research ethics review, 
and the University of Calgary’s Conjoint Health Research 
Ethics Board advised that it would not be necessary or 
appropriate, consistent with the ruling of the federal Sec-
retariat on Research Ethics that “an interesting clinical 
case would not fall within the definition of research in 
the second edition of the Tri-Council Policy Statement: 
Ethical Conduct for Research Involving Humans (TCPS 
2), to the extent that these reports are simply anecdo-
tal accounts of individual cases.” Ultimately, this study 
was reviewed and approved by St. Michael’s Hospital’s 
Research Ethics Board.
The purpose of this analysis was to examine hospitali-
zation costs for mental health care from 1997 to 2003 for 
a woman with serious mental illness. From 1997 to 2001 
she received only conventional treatment. In Decem-
ber 2001, she transitioned to a broad-spectrum micro-
nutrient formula and off of all conventional psychiatric 
medications.
We conducted a secondary data analysis focused on 
this case study. Data on hospital admission and cost were 
obtained from the discharge abstract database (DAD) at 
the Canadian Institute for Health Information (CIHI). 
With the data, we examined the trend of hospitalization 
cost with respect to the received treatment over time in 
Canada from the perspective of public health care payer 
(i.e., Ministry of Health). Costs are reported in 2015 
Canadian dollars.
Results
From 1997 to 2003 (the study period), our case study’s 
residence included Ontario (1997–2003), British Colum-
bia (1998), and Alberta (2002–2003). Based on the data 
availability, we focused our analysis mainly on hospitali-
zation cost and excluded outpatient costs of psychiatric 
appointments, medications, etc. The findings showed that 
the case study’s hospitalization cost from 1997 to 2001 
ranged from $4685 to $139,931 per year, with the average 
over 5 years being approximately $59,864. Figure 1 shows 
the total hospitalization costs from 1997 to 2003.
Excluded from the Figures and analyses were three hos-
pitalizations not related to mental health: in 2001 Marie 
underwent a urinary tract/bladder procedure, and in 
January 2003 she was hospitalized twice for pregnancy-
related treatments (the second of which was the birth of 
her son).
On December 1, 2001, Marie began taking a micro-
nutrient formula and reports that she has not required 
hospitalization for psychiatric care since then. A psy-
chiatric report dated April 1, 2005 (prepared as part of a 
civil claim for unjust dismissal) described her use of the 
micronutrient formula this way: “it is probably true that 
it is the most effective single treatment which [Marie] has 
tried.” At the present time, Marie reports that she takes 
an average of five capsules/day, and that she does “…
notice a difference in my attitude (much more positive) 
and efficiency to deal with stress, when on nutrients. I am 
































Mental health-related hospitalization cost by year (1997 - 2003)
Fig. 1 Mental health-related hospitalization cost by year (1997–
2003). Conventional care was provided 1997–2001. Micronutrient 
treatment began December 1, 2001
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As many others do, Marie now adjusts her dosage for 
her stress level, so her cost for the micronutrients cur-
rently (2016) is about $60/month ($720/year). She is 
currently employed and is actively involved in volun-
teer work on matters related to national mental health 
initiatives.
Another cost evaluation that may be informative is to 
compare Marie’s annual current cost of $720 for micro-
nutrients to a typical cost of outpatient care for mental 
health problems. In the study by Simpson and colleagues 
cited above [2], patients being discharged from hospital 
were randomized to either three months of an outpa-
tient peer-support treatment program or to treatment 
as usual, consisting of care from mental health services. 
Since they did not find a group difference, we pooled 
their costing data for both groups over three months to 
compare to Marie’s annual cost of about $720. Taking 
the costs they provided for three months, extrapolating 
to twelve months, and converting from British pounds 
in order to compare to the current case report, we 
found that annual costs ranged from $17,152 to $27,796 
(depending on whether missing data were excluded or 
imputation procedures were employed). Based on the 
average of those two ($22,474), we can conclude that the 
cost of micronutrient treatment is approximately 3% of 
an individualized peer support outpatient program; this 
estimate is remarkably similar to the 2% calculated in the 
previously published case report [21].
Discussion
Since beginning the micronutrient formula in December 
2001, Marie’s healthcare costs have decreased: she has 
not required hospitalization for psychiatric problems, 
she receives no outpatient psychiatric treatment, and 
she takes no psychiatric medications. These findings are 
consistent with the previously-published cases of two dif-
ferent children with severe psychotic disorders [20, 21]. 
Marie continues to pay for her micronutrients herself 
as there is no public coverage. The cost of the micronu-
trients on an annual basis is <10% of the annual cost of 
hospitalization during the 5-year period of conventional 
treatment from 1997 to 2001.
The benefits of the micronutrients appear to be long-
lasting. The two children previously reported [20, 21] 
have been followed for eight and seven years, respec-
tively, and Marie has now been well for 15 years on the 
micronutrients. The fact that the reported benefits have 
been sustained is consistent with other published data 
demonstrating long-term benefit [22, 23], as well as logic: 
it is difficult to imagine that human metabolism would 
‘habituate’ to the micronutrients which we have evolved 
to require and which constitute the foundation of our 
need to consume food on a daily basis.
Case studies have limitations, not the least of which 
is the fact that they fall low in the hierarchy of levels of 
evidence. Nevertheless, much can be learned from analy-
ses such as the present one, and over-reliance on RCTs is 
now a recognized problem in the medical literature [24].
Another limitation in the current analysis is that there 
was little information available on healthcare utilization 
outside of inpatient hospitalization. For instance, there 
were four visits to emergency rooms detected in Alberta, 
for a total cost of less than $40. Those were not included 
in the findings. Our analysis focused mainly on hospi-
talization cost from the Ministry of Health’s perspec-
tive. There may be additional costs which the analysis 
missed; for example, costs associated with productivity 
loss and outpatient physician visits which Marie reports 
were often weekly for about 5 years. Finally, the disability 
pension cost illustrated in Fig. 2 is based on the patient’s 
report that she received about $2000/month during this 
period. Given the seriousness of her previous mental 
health problems, her family convinced her not to return 
to work for several more years, which is why the disability 
costs displayed in Fig. 2 extended into 2009. All in all, we 
suspect our estimate is a conservative estimate of the cost 
































Fig. 2 Annual costs for hospitalization, disability payments, and 
micronutrients. Hospitalization costs are based on data from Cana-
dian Institute for Health Information (CIHI). Costs for provincial dis-
ability payments and self-funded micronutrients are patient-reported 
estimates. *Disability payments continued until 2009 as explained in 
the text
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Conclusions
There is now a rich literature showing the effectiveness of 
micronutrient treatment of mental health disorders for a 
range of symptoms [3, 12]. Included in this literature are 
two prior cases of psychotic disorders [20, 21], and in one 
of those the use of micronutrients resulted in <2% of the 
cost of conventional inpatient mental health treatment. 
The current case report adds to the literature on this 
topic, showing that micronutrients are far less expensive 
(and apparently more effective in some cases) than con-
ventional care.
There are at least two reasons for policy makers in 
health care systems to take note of these accumulat-
ing findings. First, because there is no standard insur-
ance or government reimbursement for broad-spectrum 
micronutrient formulas right now, there are many people 
who do not take them because of the cost that they must 
personally absorb. This is unfortunate because the large 
effect sizes reported in the various group studies indicate 
that there is significant potential, but this potential ben-
efit is being missed. Second, it is clearly less expensive for 
governmental healthcare systems to cover the costs of 
micronutrient therapy than to pay for conventional care 
(e.g., hospitalization, psychiatric appointments, and med-
ications). This opportunity for financial savings would 
allow the cash-strapped healthcare system to cover other 
much-needed care.
Patient’s perspective
The following statement was written by Marie, looking 
back on her mental health over the past 20 years:
“I have survived an overwhelming and dangerous jour-
ney of treatment, only to discover that what I actually 
needed was to feed my brain and recognize I was hav-
ing a normal reaction to trauma and stress. It may sound 
strange to some people, but the truth is that I am well 
because I did not do what my doctors told me. I did not 
accept their diagnoses, labels, opinions or treatment, and 
there were many over the years.  Ultimately, I did it my 
way and I’m alive because of it.
The important questions for me are these: (1) Why, 
when we know micronutrient therapy can help bring 
mental and emotional wellness, do we continue to ignore 
it in our system of health care? (2) Why, when we know 
the possibilities of healing with nutrition, and that it 
is safe and non-addictive, do we not choose this path 
of treatment prior to drugs that can be damaging and 
addictive?
Both questions boil down to the same thing: why, 
within a so-called educated society and mental health 
care system, do we choose to invest in the most danger-
ous and expensive protocol first? This is the billion dollar 
question.”
Abbreviation
RCT: randomized controlled trial.
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